• TRIM21–ERK1/2 Signaling in Pituitary Adenomas

  2026-10-07

  The 2025 Neuro-Oncology study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma proliferation, and dopamine-agonist resistance. Its integrated genetic, biochemical, animal, and drug-screening evidence nominates TRIM21 as a research target while showing that Quisinostat-associated effects require further mechanistic and translational validation.

• 10 mM dNTP Mixture as an Assay Control

  2026-10-07

  Explore how the 10 mM dNTP mixture functions as a defined DNA synthesis reagent and an important control variable in molecular biology. This article connects nucleotide composition with the interpretation of nucleic-acid delivery studies while clearly separating reagent effects from cellular trafficking biology.

• eIF4F–AKT1–EZH2 Inhibition in BRAFV600E Melanoma

  2026-10-06

  The reference study identifies coordinated ERK1/2–EZH2 and AKT1–eIF4E signaling as a mechanism by which BRAFV600E melanoma cells resist eIF4F-complex and BRAF inhibition. Its main innovation is the use of combined eIF4F, EZH2, and AKT1 blockade to improve suppression of resistant melanoma models, while also showing that resistance-associated signaling is temporally distinct and mechanistically interconnected.

• Polygodial and TRPA1 Channel Activation

  2026-10-06

  Polygodial is a research compound described as a TRPA1 channel activator. The available 2024 study supports a TRPA1-linked calcium/NFAT pathway in nasal epithelial cells, but it does not establish that polygodial itself produced those reported epithelial outcomes.

• Entecavir and HBV Resistance: Reading the Evidence

  2026-10-05

  Entecavir is a potent HBV polymerase inhibitor, but resistance risk depends strongly on prior nucleos(t)ide exposure. This evidence-focused analysis explains what the 2024 meta-analysis reveals, where its estimates are robust, and where clinical and surveillance gaps remain.

• LNP mRNA Vaccine Design for RSV: Study Findings

  2026-10-05

  A 2025 Journal of Pharmaceutical Investigation study developed and evaluated a lipid nanoparticle system for intramuscular delivery of mRNA encoding a conserved region of the RSV G glycoprotein. The preclinical formulation showed strong expression, antibody and T-cell responses, and complete protection in the reported RSV challenge model, while its relevance beyond this antigen, formulation, and animal setting remains to be established.

• Sulfachloropyridazine in E. tenella Cecal Omics

  2026-10-04

  The 2022 Microbial Pathogenesis study combined 16S rRNA gene sequencing with LC-MS/MS metabolomics to examine how Eimeria tenella infection and treatment reshape the chicken cecal environment. Its findings distinguish an ethanamizuril-associated microbiota profile, reduced Escherichia-Shigella after sulfachlorpyridazine treatment, and comparatively limited effects from the low-dose combination, while emphasizing that these are context-specific associations rather than proof of mechanism.

• Isorhamnetin: PI3K/Akt Evidence Guide

  2026-10-03

  Isorhamnetin is a flavonoid compound linked to PI3K/Akt activation in a preclinical porcine oocyte study. The evidence supports research into oxidative stress, apoptosis, mitochondrial regulation, and endoplasmic reticulum stress, but it does not establish human fertility efficacy or a universal pathway effect.

• 293T Cells for CRISPR Workflow Design

  2026-10-02

  293T Cells provide a human cell-based platform for transient expression, reporter testing, and genome-engineering workflows, but the cells do not perform CRISPR editing without externally supplied editing components. Their biological rationale derives from the HEK293 lineage and SV40 large T-antigen expression, while multiplex CRISPR applications require independent guide, nuclease, and control design.

• Dutasteride Workflows for Prostate Research

  2026-10-01

  Dutasteride supports mechanism-driven studies that connect dual 5-alpha-reductase inhibition with DHT depletion, growth control, and apoptosis readouts. This workflow emphasizes solvent discipline, orthogonal target-engagement assays, and a carefully bounded comparison with metabolite–immune signaling research.

• 7-AAD Cell Viability Assay Kit for CAR-T Readouts

  2026-10-01

  The 7-AAD Cell Viability Assay Kit provides a red-fluorescence membrane-integrity readout for necrotic and late apoptotic cells. Its compatibility with flow cytometry, fluorescence microscopy, and multiplex markers makes the 7-amino actinomycin D assay useful for evaluating cytotoxicity and fratricide in CD38 CAR-T research.

• Resiquimod (R-848) for Ablation Immunotherapy

  2026-09-30

  Resiquimod (R-848) connects TLR7/8 activation with practical assays for cytokine release, dendritic-cell maturation, macrophage polarization, and localized tumor-ablative immunotherapy. This guide translates a thermal-protective hydrogel study into controlled workflows that distinguish compound activity from heat injury, formulation effects, and delivery kinetics.

• HyperScribe™ Cy5 RNA Labeling Kit: Lab Guide

  2026-09-30

  Learn how SKU K1062 can support reproducible fluorescent RNA probe synthesis when viability, proliferation, or cytotoxicity assays require mechanistic transcript-level context. This scenario-based guide covers probe design, T7 transcription, Cy5-UTP optimization, interpretation, and practical product selection.

• Inonotus obliquus Polysaccharide in Rheumatoid Arthritis

  2026-09-29

  This study combines network pharmacology with cell-based and collagen-induced arthritis experiments to investigate how Inonotus obliquus polysaccharide (IOP) affects rheumatoid arthritis. The findings connect IOP with suppression of NF-κB and NLRP3 inflammasome signaling, reduced inflammatory activity, and inhibition of rheumatoid synovial fibroblast-like behavior.

• 293T Cells for Multiplex CRISPR Assay Design

  2026-09-29

  293T Cells provide a practical platform for testing delivery, guide combinations, and readouts in multiplex CRISPR workflows. This article explains how to use them as an assay-calibration system while recognizing the biological limits that separate transfection feasibility from disease-relevant validation.

8590 records 1/573 page Next 12345 下5页 Last page